Missouri University of Science and Technology

Scholars' Mine
Materials Science and Engineering Faculty
Research & Creative Works

Materials Science and Engineering

01 Jan 2016

Antibody Targeting Facilitates Effective Intratumoral SiRNA
Nanoparticle Delivery to HER2-Overexpressing Cancer Cells
Maria C. Palanca-Wessels
Garrett Booth
Anthony J. Convertine
Missouri University of Science and Technology, convertinea@mst.edu

Brittany B. Lundy
et. al. For a complete list of authors, see https://scholarsmine.mst.edu/matsci_eng_facwork/2252

Follow this and additional works at: https://scholarsmine.mst.edu/matsci_eng_facwork
Part of the Materials Science and Engineering Commons

Recommended Citation
M. C. Palanca-Wessels et al., "Antibody Targeting Facilitates Effective Intratumoral SiRNA Nanoparticle
Delivery to HER2-Overexpressing Cancer Cells," Oncotarget, vol. 7, no. 8, pp. 9561-9575, Impact Journals
LLC, Jan 2016.
The definitive version is available at https://doi.org/10.18632/oncotarget.7076

This Article - Journal is brought to you for free and open access by Scholars' Mine. It has been accepted for
inclusion in Materials Science and Engineering Faculty Research & Creative Works by an authorized administrator
of Scholars' Mine. This work is protected by U. S. Copyright Law. Unauthorized use including reproduction for
redistribution requires the permission of the copyright holder. For more information, please contact
scholarsmine@mst.edu.

Oncotarget, Vol. 7, No. 8

www.impactjournals.com/oncotarget/

Antibody targeting facilitates effective intratumoral siRNA
nanoparticle delivery to HER2-overexpressing cancer cells
Maria C. Palanca-Wessels1,2,*, Garrett C. Booth1, Anthony J. Convertine3, Brittany
B. Lundy3, Geoffrey Y. Berguig3, Michael F. Press4, Patrick S. Stayton3, Oliver W.
Press1,3
1

 linical Research Division and Center for Intracellular Delivery of Biologics, Fred Hutchinson Cancer Research Center,
C
Seattle, WA, USA

2

Department of Medicine, Hematology Division, University of Washington, Seattle, WA, USA

3

Department of Bioengineering and Center for Intracellular Delivery of Biologics, University of Washington, Seattle, WA, USA

4

Department of Pathology, University of Southern California, Los Angeles, CA, USA

*

 his work was performed in Seattle, WA, USA. M.C.P.W. performed this work while at the Fred Hutchinson Cancer Research
T
Center, but is now employed by Seattle Genetics

Correspondence to: Oliver W. Press, e-mail: press@u.washington.edu
Keywords: HER2 antibody, siRNA, targeted antibody delivery, ovarian cancer, breast cancer
Received: August 28, 2015     Accepted: January 19, 2016     Published: January 30, 2016

ABSTRACT
The therapeutic potential of RNA interference (RNAi) has been limited by
inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can
be effectively achieved by antibodies directed against highly expressed cancer cell
surface receptors. We investigated the utility of linking an internalizing streptavidinconjugated HER2 antibody to an endosome-disruptive biotinylated polymeric
nanocarrier to improve the functional cytoplasmic delivery of siRNA in breast and
ovarian cancer cells in vitro and in an intraperitoneal ovarian cancer xenograft model
in vivo, yielding an 80% reduction of target mRNA and protein levels with sustained
repression for at least 96 hours. RNAi-mediated site specific cleavage of target mRNA
was demonstrated using the 5’ RLM-RACE (RNA ligase mediated-rapid amplification
of cDNA ends) assay. Mice bearing intraperitoneal human ovarian tumor xenografts
demonstrated increased tumor accumulation of Cy5.5 fluorescently labeled siRNA
and 70% target gene suppression after treatment with HER2 antibody-directed siRNA
nanocarriers. Detection of the expected mRNA cleavage product by 5’ RLM-RACE assay
confirmed that suppression occurs via the expected RNAi pathway. Delivery of siRNA
via antibody-directed endosomolytic nanoparticles may be a promising strategy for
cancer therapy.

for suppression of genes critical for tumor growth
or resistance to chemotherapy may improve clinical
outcomes and patient survival. The demonstration of the
RNAi-mediated mechanism of target mRNA cleavage in
human tumors from patients treated in Phase I clinical
trials provides hope for clinical use of siRNA, however,
the major obstacle of cell specific delivery remains to be
overcome. [3, 4]
The selective recognition of tumors by antibodies
has been harnessed to directly elicit apoptosis, stimulate
the immune-mediated clearance of cancer cells, or
target cytotoxic agents to cancer cells. HER2 (also
known as ERBB2 or NEU) is an internalizing cell

INTRODUCTION
The discovery of the RNA interference (RNAi)
mechanism over a decade ago by Andrew Fire and
Craig Mello stimulated intense interest in the potential
application of short interfering RNA (siRNA), not only
as a useful tool for the mechanistic study of cellular
pathways but more significantly as a novel disease
therapeutic. The ensuing years have resulted in a flurry
of preclinical investigations and early phase clinical trials
designed to test the utility of siRNA for the treatment of
a variety of human diseases. [1, 2] In particular, siRNA
www.impactjournals.com/oncotarget
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surface receptor overexpressed or mutated in a variety
of solid tumors including breast, gastric, lung and
ovarian cancers. [5–9] Treatment with trastuzumab, a
humanized mouse antibody directed against HER2, has
become the standard of care for HER2-overexpressing
breast cancer [6] and HER2-overexpressing metastatic
gastric cancer. [10] HER2 has additionally been
investigated as a portal through which receptor targeted
antibodies or aptamers can deliver peptides, [11–13]
siRNA [14, 15] or small molecule drugs [16] into cells.
Recently, a drug conjugated form of trastuzumab (adotrastuzumab emtansine) that facilitates the intracellular
delivery of the cytotoxic microtubule inhibiting agent
mertansine was approved for the treatment of metastatic
breast cancer. [17] Trastuzumab in combination with
chemotherapy improved outcomes in gastric cancer
patients, but single agent trastuzumab in ovarian cancer
patients did not extend survival, although patients were
selected for the clinical trial using relatively insensitive
immunohistochemical assays without any confirmation
of HER2 gene amplification status. [10, 18]
We previously developed a modular siRNA delivery
system using a biotinylated endosome disrupting polymer
that permits facile testing of combinations of antibody and
siRNA and can be potentially tailored to various tumor
types. [19] We hypothesized that a trastuzumab-directed
siRNA nanoparticle could be used to enhance target gene
suppression in HER2-overexpressing ovarian cancer
cells. Ovarian cancer remains the most deadly cancer in
women primarily due to its advanced state at diagnosis
and rapid development of drug resistance. Little progress
has been made over the past 20 years in improving the
overall survival of patients, approximately 40% at 5 years,
underscoring the need for novel therapeutic agents. [20]
Our group previously demonstrated the effectiveness
of siRNA delivery to cells in vitro via a pH-sensitive
endosomolytic diblock co-polymer carrier bearing an
internalizing antibody directed against the CD22 receptor
expressed on lymphoma cells. [19] The linear carrier
consists of: 1) a pH-responsive ampholyte block of
poly(DMAEMA) (dimethylaminoethyl methacrylate),
BMA (butylmethacrylate), and PAA (propylacrylic acid)
groups; 2) a cationic poly(DMAEMA) block for binding
siRNA; and 3) a terminal biotin to enable linkage to a
streptavidin-conjugated monoclonal antibody (mAbSA). Electrostatic interactions promote complexation of
siRNA to the polymeric micelles (Figure 1a). Targeted
nanoparticles are formed by subsequent addition of mAbSA which attach to exposed surface biotin on micelles.
Binding of antibody to cognate antigen stimulates
receptor-mediated endocytosis and uptake into the
tumor cell (Figure 1b). Subsequent protonation of PAA
in the acidic environment of late endosomes induces a
conformational change to predominantly hydrophobic
unimers, disrupting the endosomal membrane and
releasing siRNA into the cytoplasm. The modularity of
www.impactjournals.com/oncotarget

this system permits testing of combinations of antibodies
and siRNA customized to different tumor types. We sought
to demonstrate the versatility and effectiveness of our
polymer carrier system both in vitro and in vivo using the
HER2 antibody, trastuzumab, in a solid tumor xenograft
model of ovarian cancer.

RESULTS
Intracellular uptake of nanoparticles by HER2overexpressing cancer cells
Binding and internalization of the trastuzumabpolymer siRNA nanoparticle was confirmed by flow
cytometry in both HER2-overexpressing SKOV3 ovarian
cancer and SKBR3 breast cancer cells using fluorescent
AlexaFluor 647 labelled siRNA (Figure 2). Fluorescence
intensity after 1 hour of incubation was markedly higher
in cells exposed to nanoparticles targeted with streptavidinconjugated trastuzumab (Trast-SA) compared to nontargeted bovine herpes virus-1 antibody conjugate (BHV1SA) or naked nanoparticles. Confocal microscopy of
SKOV3 cells 24 hours after treatment with AlexaFluor 647
labeled siRNA showed a punctate pattern of fluorescence
consistent with endocytic uptake (Figure 2). Enhanced
uptake was similarly observed in SKOV3 cells using a
different HER2 antibody 10H8 which recognizes a separate
epitope on the HER2 receptor (Supplementary Figure S1a).

RNAi-mediated suppression via HER2 antibodylinked siRNA carrier
Functional delivery was assessed in both HER2overexpressing ovarian and breast cancer cells using siRNA
directed against the ubiquitously expressed glyceraldehyde3-phosphate dehydrogenase (GAPD) enzyme gene. Two
hour pulse treatment of SKOV3 ovarian cancer cells with
Trast-SA targeted nanoparticles containing GAPD siRNA
resulted in greater reduction of GAPD expression at 48 hours
compared to BHV1-SA as assessed by quantitative RT-PCR
(Figure 3a) and GAPD enzyme activity (Supplementary
Figure S1b). Verification of the RNAi mechanism of gene
suppression was accomplished by the detection of the
predicted 281 base pair fragment of GAPD mRNA using
the 5’ RLM-RACE assay (RNA ligase-mediated rapid
amplification of cDNA ends) (Figure 3b). Sequencing of
the isolated fragment verified that cleavage occurred at the
expected site in the GAPD mRNA. Robust suppression
of the GAPD gene was demonstrated for at least 96 hours
after 2 hour pulse treatment of luciferase-expressing
SKOV3 EA8 cells (Figure 3c). GAPD gene suppression
was similarly demonstrated in the HER2-overexpressing
breast cancer cell lines SKBR3 and BT-474 (Supplementary
Figure S2). Treatment of cells with nanoparticles did not
elicit cytotoxicity nor induce TLR-3 (toll-like receptor 3)
activated immune response genes STAT1 (signal transducer
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and activator of transcription-1) or OAS1 (2’-5’ oligoadenylate
synthetase-1) genes (Supplementary Figure S3).
In order to demonstrate that suppression could
be achieved using different clinically relevant siRNA
sequences, we tested the functional delivery of siRNA
designed against genes associated with chemotherapy
resistance. High levels of BCL-XL (B-cell lymphoma-extra

large, also known as BCL2L1 or BCL2-like-1) are found
in platinum resistant ovarian cancer cells and inhibition
of BCL-XL confers sensitivity to chemotherapeutic
agents. [21, 22] STAT3 (signal transducer and activator
of transcription-3) has been shown to upregulate BCL-XL
in solid tumors. [23] Significant suppression of BCL-XL
was demonstrated in SKOV3 EA8 cells pulse treated for

Figure 1: Antibody-targeted nanoparticle formation and intracellular siRNA delivery. a. The biotinylated diblock copolymer

carrier consists of two modules: (1) a biotinylated cationic block comprised of poly(DMAEMA) and (2) an amphiphilic block consisting of
DMAEMA, BMA and PPA groups. The linear polymer chains spontaneously form polymeric micelles with biotin exposed on the surface
of the micelles. Polyplexes are formed by adding siRNA which associate with micelles via electrostatic interactions. Antibody-streptavidin
conjugates (mAb-SA) are added and attach to available biotin moieties on the polymeric micelle surface resulting in antibody-targeted
nanoparticles. b. Intracellular delivery is initiated by the recognition and binding of the antibody targeted nanoparticle to the cognate
internalizing cell surface antigen on the surface of the tumor cell. Receptor-mediated endocytosis is triggered and the nanoparticle is
internalized into the cell. As endosomal maturation occurs, the pH in the endosomal compartment drops and carboxyl groups in the amphilic
block are protonated causing a conformational change of the polymer. This exposes the hydrophobic BMA side groups and disrupts the
endosomal membrane leading to release of siRNA. siRNA is incorporated into the cytoplasmic RISC complex leading to catalytic cleavage
of target mRNA and reduction of gene expression.
www.impactjournals.com/oncotarget
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Figure 2: HER2 antibody conjugate Trast-SA enhances the uptake of siRNA-containing nanoparticles into HER2overexpressing SKOV3 ovarian and SKBR3 breast cancer cells. a. SKOV3 and b. SKBR3 cells were treated continuously for 1

hour with Trast-SA or BHV1-SA bearing nanoparticles or naked nanoparticles containing AlexaFluor 647 (AF647) labeled siRNA, trypsinized,
then analyzed by flow cytometry for median relative fluorescence intensity (RFI). Representative results of 2 separate experiments are shown.
c-e. SKOV3 cells grown on chambered glass slides were treated for 2 hours with (c) fluorescent AF647 labeled siRNA alone or contained within
(d) BHV1-SA or (e) Trast-SA bearing nanoparticles prior to being rinsed and incubated with medium without nanoparticles. After 24 hours, cells
were fixed, counterstained with mounting medium containing DAPI DNA stain, then visualized by fluorescence microscopy. Images were taken
with a DeltaVision Elite wide deconvolution microscope at the original magnification of 80X. For each panel (c-e), both the fluorescence image
(right) and fluorescence image merged with its respective differential interference contrast image (left) are shown. Scale bar equals 20 microns.
www.impactjournals.com/oncotarget
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Figure 3: Suppression of GAPD gene expression by Trast-SA polymer mediated siRNA delivery in SKOV3 ovarian
cancer cells. a. SKOV3 cells were incubated for 2 hours in triplicate wells with GAPD or negative control siRNA contained in nanoparticles

bearing Trast-SA or BHV1-SA conjugates or the respective antibody conjugates alone. Medium containing nanoparticles was then replaced
with fresh medium alone and cells subsequently harvested 48 hours after the initial treatment and RNA extracted for qRT-PCR. Results
are representative of three separate experiments. b. Verification of mRNA suppression via an RNAi mechanism was performed on SKOV3
cells that were pulse treated for 2 hours with Trast-SA bearing nanoparticles containing either GAPD or negative control siRNA and RNA
extracted 48 hours later for qRT-PCR and 5’RLM-RACE analysis. The bar graph demonstrates reduction of target GAPD mRNA levels as
measured by qRT-PCR in cells treated with GAPD but not control siRNA. Below the graph, gel electrophoresis of 5’ RLM-RACE assay
products from the respective treatments showed the predicted 281 base pair GAPD mRNA cleavage product only in the Trast-SA GAPD
siRNA treated but not control siRNA or untreated cells supporting an RNAi mechanism for reduced GAPD expression. c. Sustained
suppression of GAPD expression was observed in SKOV3 EA8 luciferase expressing cells treated for 2 hours with Trast-SA containing
GAPD siRNA then analyzed for GAPD mRNA level via qRT-PCR at various timepoints after treatment.

www.impactjournals.com/oncotarget
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2 hours with Trast-SA targeted nanoparticles containing
BCL-XL siRNA (Figure 4a) and showed an expected
dose response with increasing siRNA concentrations
(Figure 4b). The predicted 309 base pair mRNA cleavage
product was demonstrated by the 5’RLM-RACE assay
in cells treated with BCL-XL siRNA but not negative
control siRNA (Figure 4c). The mRNA cleavage product
identity was verified by sequencing the cDNA band
purified from the gel. Reduction of BCL-XL protein in
cells was demonstrated by Western blot analysis (Figure
4d). Similar results were shown using a second BCL-XL
siRNA sequence (data not shown). Reduction of STAT3
mRNA was shown with qRT-PCR. Pretreatment with
Trast-SA conjugate blocked HER2-mediated uptake of
Trast-SA bearing nanoparticles containing STAT3 siRNA
as demonstrated by reduction of STAT3 gene suppression
to a level comparable to that achieved with non-targeting
BHV1-SA conjugate (Figure 4e).

Comparison of the amount of Cy5.5 in tumor and kidney
showed an average tumor to kidney ratio of 0.6 versus
50 (p=0.04) in mice treated with non-targeted siRNA or
Trast-SA targeted siRNA respectively (data not shown).
The average tumor to liver ratio of Cy5.5 was 1.8 versus
39 (p=0.002) in mice treated with non-targeted siRNA or
Trast-SA targeted siRNA, respectively (data not shown).

Effective suppression of target genes in
intraperitoneal ovarian tumors
Functional delivery of GAPD siRNA to tumors
in vivo was investigated. Mice bearing intraperitoneal
SKOV3 EA8 tumors were divided into groups with a
similar average tumor bioluminescence and treated with
the following: PBS, Trast-SA alone, BHV1-SA targeted
nanoparticles containing GAPD siRNA or Trast-SA
targeted nanoparticles containing either control or GAPD
siRNA. Mice were treated daily for two consecutive
days at a dose of 4 mg/kg siRNA, then sacrificed 72
hours after the last dose. Intraperitoneal tumors were
excised and RNA extracted. Reduction of GAPD gene
expression by 70% with Trast-SA targeted nanoparticles
containing GAPD siRNA was demonstrated via qRT-PCR
compared to a 25% reduction with BHV1-SA non-targeted
nanoparticles (Figure 6a). Additional mice were treated
on the same schedule but at a dose of 2 mg/kg siRNA
(Figures 6b, 6c). The 281 base pair predicted GAPD
mRNA cleavage product was detected using the 5’RLMRACE assay in ovarian tumor tissue derived from mice
treated with Trast-SA bearing nanoparticles containing
GAPD siRNA but not in mice treated with Trast-SA
nanoparticles containing negative control siRNA or TrastSA alone thus verifying RNAi-mediated GAPD gene
suppression (Figure 6c). No induction of TLR3-activated
immune response genes (OAS1 and STAT1) was detected
(Supplementary Figure S4a, 4b). A minor three-fold
increase in expression of mouse Ifit1 (interferon-induced
protein with tetratricopeptide repeats-1), another marker
of immune response, was detected in the spleens of mice
treated with siRNA containing nanoparticles bearing either
Trast-SA or BHV1-SA (Supplementary Figure S4). No
marked changes in pancreatic, hepatic, or renal function,
nor elevation in creatinine kinase or glucose were detected
between treatment groups (data not shown).

Localization of siRNA to intraperitoneal ovarian
tumor with HER2 antibody
Ovarian cancer spreads locally within the abdominal
cavity leading to tumor studding of peritoneal surfaces,
blockage of lymphatic drainage and development of
ascites. We used an intraperitoneal xenograft mouse
model to recapitulate the typical clinical presentation in
patients. Since assessment of intraperitoneal tumor burden
by palpation is unreliable, we utilized the luciferaseexpressing SKOV3 clone EA8 to permit visualization
of tumors in vivo with bioluminescence imaging. Mice
bearing SKOV3 EA8 intraperitoneal ovarian tumors were
imaged after luciferin injection by the IVIS Xenogen
imaging system and separated into treatment groups
with similar tumor burden as measured by average
bioluminescence intensity. Mice were then injected with
siRNA labeled with the near-infrared dye Cy5.5. Mice
were sacrificed and organs were removed and imaged
in an ex vivo fashion. We observed enhanced in vivo
localization of siRNA delivered by trastuzumab-directed
polymer to intraperitoneal ovarian tumors. Combined
bioluminescence and fluorescence imaging after 24 hours
revealed the accumulation of Cy5.5 siRNA in the kidneys
whereas Cy5.5 siRNA administered within trastuzumabtargeted nanoparticles was still present in tumors at this
timepoint (Figure 5a, 5b). Quantification of Cy5.5 was
accomplished by homogenizing tissue and measuring the
amount of Cy5.5 fluorescence relative to a standard curve
generated by a known quantity of Cy5.5 labeled siRNA.
This revealed a marked accumulation of Cy5.5 in tumors
removed from mice treated with Trast-SA bearing siRNA
nanoparticles compared to free siRNA. Tumors from mice
treated with Trast-SA targeted nanoparticles contained an
average of 228 picomoles of Cy5.5 per gram of tumor
tissue compared to 11 picomoles in tumors from mice
treated with non-targeted siRNA, p=0.005 (Figure 5c).
www.impactjournals.com/oncotarget

DISCUSSION
Effective intracellular delivery to target cells in vivo
is undoubtedly the most difficult hurdle to overcome in
the development of oligonucleotide therapeutics. Early
phase clinical trials testing therapeutic siRNA in humans
have shown favorable results, but it is still uncertain which
delivery vehicle will ultimately prove to be the most
effective for clinical application. We present encouraging
preclinical data testing a modular antibody-directed
9566
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Figure 4: Effective suppression of oncogenes Bcl-xL and STAT3 in cancer cells. SKOV3 EA8 cells were treated for 2 hours

with nanoparticles bearing Trast-SA or BHV1-SA conjugates and containing 25 nM siRNA directed against BCL-XL or a scrambled negative
control bearing no homology to any known gene sequence. Cells were rinsed to remove medium containing nanoparticles and fresh medium
introduced. After 48 hours, cells were harvested and RNA collected for a. qRT-PCR analysis and c. detection of the expected 309 base pair
BCL-XLmRNA fragment (red arrow) by the 5’RLM-RACE assay. SKOV3 EA8 cells were similarly treated for 2 hours with Trast-SA targeted
nanoparticles at a dose range (15 to 50 nM) of BCL-XL siRNA or negative control siRNA at 25 or 50 nM. RNA or protein was collected at
48 hours for b. qRT-PCR analysis and d. Western blot respectively. Results from cells treated with 25 nM or 50 nM negative control siRNA
are shown since BCL-XL expression levels did not vary by negative control siRNA dose. HER2 receptors on SKOV3 EA8 cells were blocked
by incubation with 37.5 nM of Trast-SA alone for 30 minutes prior to 2 hour incubation with Trast-SA targeted polyplexes containing 25 nM
siRNA directed against STAT3. Other cells were treated with nanoparticles containing negative control or STAT3 siRNA bearing the indicated
antibody conjugate targeting without preincubation. RNA was harvested 48 hours later and STAT3 levels assessed by qRT-PCR e. All qRTPCR analyses were performed for triplicate samples with standard deviation shown. Similar results were observed in duplicate experiments.
www.impactjournals.com/oncotarget
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Figure 5: Intraperitoneal ovarian tumor localization of Cy5.5 fluorescently labeled siRNA after administration
of HER2 targeted carrier. Athymic mice were injected intraperitoneally with SKOV3 EA8 luciferase expressing cells and tumor

establishment verified by bioluminescence imaging using the Xenogen IVIS system. Two weeks after tumor cell injection, 4 mice per
treatment group were injected with phosphate buffered saline (PBS), 2 mg/kg Cy 5.5 labelled siRNA alone or contained within TrastSA targeted nanoparticles. Twenty-four hours later, mice were injected with luciferin, euthanized, and organs (heart, lungs, liver, spleen,
kidneys, tumor) removed. Tissues were imaged ex vivo for both a. bioluminescence to identify luciferase expressing tumor cells and b.
fluorescence to visualize siRNA biodistribution. c. Tumor tissue was weighed, homogenized in PBS and pelleted. Cy5.5 fluorescence
intensity in the supernatant was measured at 675 nm excitation and 694 nm emission wavelength. The picomolar amount of Cy5.5 per gram
in each tissue was determined by relating the measured fluorescence to a standard curve generated by known quantities of Cy5.5 siRNA.
www.impactjournals.com/oncotarget
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Figure 6: RNAi mediated target gene silencing within intraperitoneal ovarian cancer tumors after HER2 antibody
directed siRNA delivery. Athymic mice bearing intraperitoneal SKOV3 EA8 tumors verified by bioluminescence imaging were treated
with Trast-SA or BHV1-SA conjugate bearing nanocarriers containing negative control or GAPD siRNA, Trast-SA alone or PBS at doses
of a. 4 mg/kg (n=5 mice per group) or b, c. 2 mg/kg siRNA (n=3 mice per group) for two doses administered 24 hours apart. Mice were
sacrificed 72 hours after the second dose and tumors collected for (a,b) qRT-PCR analysis and (c) detection of the 281 base pair GAPD
mRNA cleavage product by 5’RLM-RACE assay. Error bars represent the standard deviation for qRT-PCR analyses. Asterisk indicates a
significant difference (p<0.01) using the Student t-Test with one-tailed distribution between Trast-SA GAPD and BHV1-SA GAPD.
www.impactjournals.com/oncotarget
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biotinylated polymer carrier that can be easily adapted
to different tumor types by varying the combination of
antibody conjugate and target siRNA sequence.
We have demonstrated that this antibodydirected carrier can deliver functionally active siRNA
to both ovarian and breast cancer cells overexpressing
HER2. Two internalizing HER2 antibody conjugates
(trastuzumab and 10H8) that recognize separate epitopes
effectively facilitated intracellular delivery of siRNA.
Non-specific limited uptake of particles bearing nontargeting BHV1-SA was observed and may be largely
due to macropinocytosis which can be upregulated in
cancer cells. [24] Blocking HER2 receptors with free
Trast-SA conjugate prior to treatment with trastuzumabbearing nanoparticles reduced the level of suppression to
that seen with non-targeting BHV1-SA, supporting the
presence of an alternate pathway of uptake independent
of HER2 receptor binding. The residual cationic charge
on nanoparticles can promote non-specific association
with negatively charged components on the cell
surface membrane. Charge neutral carriers may reduce
spontaneous non-targeted cellular uptake and our group
is exploring alternative non-cationic carrier chemistries
that utilize direct covalent disulfide linkage of siRNA to
polymer rather than electrostatic interaction. [25] These
neutral carriers are effective in vitro but require a higher
siRNA concentration and longer continuous incubation
time to achieve a level of gene suppression comparable
to the antibody-targeted cationic diblock polymer used
in the studies described in this report. Incorporation of
an internalizing antibody or ligand moiety to the neutral
siRNA carrier may counteract any loss of cellular uptake
due to diminished charge interaction and improve the
specificity of delivery and reduce the in vivo toxicity that
can be observed with cationic carriers. Efforts to test this
hypothesis are ongoing.
Verification of the intended mechanism of action
is important in evaluating the efficacy of a therapeutic
carrier. Detection of the predicted target mRNA cleavage
product by 5’RLM-RACE is the gold standard for
confirmation of RNAi-mediated gene suppression. [26]
We showed that the predicted mRNA cleavage products
were detectable both by size on agarose gel electrophoresis
and by sequencing of the PCR product using two different
siRNAs designed against either GAPD or BCL-XL genes
in cultured ovarian cancer cells. Furthermore, site specific
cleavage of target mRNA was detected in mouse xenograft
ovarian tumor tissue (Figure 6c) supporting the functional
in vivo activity of siRNA delivered by HER2-targeted
polymer carrier. Because activation of TLR3 by polymermediated siRNA delivery can lead to unintended effects
from activation of the innate immune response, induction
of OAS1 and STAT1 genes was assessed in tumors and
found not to be upregulated in vivo. However, mouse
Ifit1 gene expression was increased approximately 3
to 4-fold in mouse spleen after treatment with Trast-SA
www.impactjournals.com/oncotarget

or BHV1-SA targeted nanoparticles suggesting modest
immune response activation. The significance of this low
level of Ifit1upregulation is uncertain. Notably, siRNA
treated mice exhibited no difference in behavior or
appearance than mice receiving PBS alone. In comparison,
a lipid-based carrier has been shown to induce a 247fold increase of Ifit1 mRNA expression and detectable
serum interferon alpha levels in mice treated with 2 mg/
kg unmodified siRNA compared to PBS treatment. [27]
Mitigation of the immune response may be achieved by
use of 2’O-methyl modification of siRNA sequences [27]
or pretreatment with dexamethasone. [28]
In conclusion, we have demonstrated the successful
in vitro and in vivo antibody-targeted functional delivery
of siRNA to HER2-overexpressing cancer cells. RNAimediated cleavage of target mRNA was verified as the
mechanism of gene suppression. Antibody-targeted
nanoparticle delivery of siRNA incorporating endosomolytic
polymer carriers may be a useful strategy for cancer therapy.
Similar targeted carriers to deliver small molecule drugs or
peptides may also be promising. Future directions include
testing therapeutic siRNA sequences both as monotherapy
and in combination with chemotherapy with in vivo cancer
models. Evaluation of other internalizing receptors expressed
on a higher proportion of ovarian tumors than HER2 such as
mesothelin is also of interest. [29]

MATERIALS AND METHODS
Cell lines and media
The SKOV3, SKBR3 and BT-474 cell lines were
obtained from the American Type Culture Collection
(ATCC; Manassas, VA). Authentication of the cell line was
assured by the provider. All three of these cell lines have
HER2 gene amplification and overexpression. Multiple
aliquots were frozen from cells continuously passaged
no longer than 3 months after initial receipt. Cells for
experiments were passaged continuously for no longer
than 3 months before being discarded and fresh aliquots
resuscitated. The SKOV3 luciferase-expressing clone EA8
was generated by retroviral transduction of SKOV3 cells
with a retrovirus encoding the firefly luciferase-Thy1.1Neo construct [30] followed by flow cytometric sorting
for Thy1.1 expression and selection of Thy1.1 expressing
cells with G418. SKOV3 EA8 was subsequently cloned by
limiting dilution. All cell culture reagents were obtained
from Invitrogen (Carlsbad, CA) except for fetal bovine
serum (FBS) obtained from Thermo Scientific Hyclone
(Logan, UT). SKOV3, SKOV3 EA8 and SKBR3 cells
were grown in RPMI containing 10% fetal bovine serum,
100 IU/ml penicillin, 100 mcg/ml streptomycin, and 2
mM L-glutamine with the addition of 800 mcg/ml G418
for the SKOV3 EA8 cells. BT-474 cell lines were grown
in Hybri-Care Medium (ATCC) with 10% FBS. All cells
were maintained at 37°C in 95% air/5% CO2 incubator.
9570
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Negative Control siRNA (#1027287; Invitrogen) and
added to cells in media containing 5% FBS at a final
concentration of 20 nM of siRNA. After incubation at
37°C to allow internalization, cells were trypsinized
and acid washed to remove residual surface bound
nanoparticles and intracellular fluorescence measured
on a BD FACS Canto flow cytometer with untreated
cells set as a background reference as previously
described. [19]

Polymer was synthesized as previously described.
[19] BHV1 (IgG1 anti-bovine herpes virus-1 antibody)
was produced from a hybridoma obtained from ATCC and
purified from ascites fluid over a HiTrap Protein G HP column
(GE Healthcare; Piscataway, NJ). Trastuzumab used for
experiments was clinical grade (Genentech; San Francisco,
CA). 10H8 (an internalizing antibody to HER2) was produced
in the laboratory of Michael F. Press (University of Southern
California) as published. [31] Streptavidin conjugations to
trastuzumab, BHV1 and 10H8 antibodies were performed
by Donald K. Hamlin (University of Washington) using
previously published techniques. [32, 33]

Fluorescence microscopy
SKOV3 EA8 cells were plated at 50,000/well in
2-well chamber slides and allowed to adhere overnight.
Polyplexes were formed as above using AlexaFluor
647-labeled AllStars Negative Control siRNA
(#1027287; Invitrogen) and added to cells in media
containing 5% FBS at a final concentration of 25 nM
of siRNA. After incubation at 37 °C for 2 hours, cells
were rinsed to remove unbound nanoparticles and fresh
medium added. After 24 hours, cells were rinsed three
times in PBS, fixed with 10% neutral buffered formalin
for 15 minutes, and rinsed again in PBS prior to being
coverslipped with Prolong Gold antifade reagent with
DAPI (Invitrogen). Random fields were imaged at 60x
(oil) with a DeltaVision Elite wide-field deconvolution
microscope (Applied Precision, Issaquah, WA) fitted
with a Photometrics HQ scientific grade cooled CCD
camera and an Olympus 60×/1.42 Plan Apochromatic
objective. Acquisition settings were constant for the
AlexaFluor 647 signal. Three-dimensional data sets
consisting of optical sections at 0.2 micron spacing were
collected with the manufacturer's SoftWoRx software,
and deconvolved using a constrained iterative algorithm.
Data sets were processed to normalize intensities to
the same scale using SoftWoRx software. Merging the
data sets with their respective differential interference
contrast (DIC) images was done with public domain
software ImageJ.

Polymeric micelle formation and transfection
Polymeric micelles were reconstituted from
lyophilized polymer to a concentration of 1 mg/ml or 10
mg/ml in sterile PBS for in vitro or in vivo experiments
respectively as previously described. [19] Polymer was
added to siRNA at a polymer:siRNA molar ratio of 3:1
and incubated for 30 minutes at room temperature. The
mAb-SA conjugates were added to polyplexes at 1:1
conjugate to available biotin molar ratios. Dynamic
light scattering measurements of the polymeric micelles
and siRNA complexes (N/P ratio = 3) in 150 mM PBS
at pH 7.4 yielded hydrodynamic diameters of 34 nm and
37 nm respectively. The surface charge of the siRNApolymer complexes (N/P ratio = 3), based on ζ-potential
measurements was found to be 4 mV, which suggests that
particles are slightly positive under these conditions.
Cells were plated at a cell density of 50,000/
well in triplicate on the day prior to treatment. Cells
were treated with polyplexes for 2 hours in medium
containing 5% FBS followed by a medium change to
10% FBS. Cells were harvested at 48 or 72 hours posttreatment for RNA and protein extraction respectively.
The siRNA sequences were as follows: glyceraldehyde-3phosphate dehydrogenase (GAPD) (sense strand 5’-GGU
CGGAGUCAACGGAUUUTT-3’; Integrated DNA
Technol
ogies; Coralville, IA); STAT3 (sense strand
5’-GCCUCUCUG CAGAAUUCAATT-3’, Integrated
DNA Technologies); BCL-XL (sense strand 5’-GCUGGA
GUCAGUUUAGAUGATT-3’; siRNA ID# s1921; sense
strand 5’-GGAACUCUAUGGGAACAAUTT-3’; siRNA
ID# s1922, Ambion); Ambion In Vivo GAPDH siRNA
Cat#4457291; Ambion In Vivo Bcl2L1 Cat#4457308;
Silencer Negative Control #1 siRNA (Catalog AM4611;
Ambion).

Quantitative RT-PCR
RNA was isolated using the RNeasy mini kit
(Qiagen; Valencia, CA) and reverse transcribed using
TaqMan Reverse Transcription reagents (Applied
Biosystems; Carlsbad, CA). PCR reactions were run
in duplicate using an ABI Prism 7900HT real-time
PCR instrument. Primers with FAM and VIC-labeled
compatible probes for multiplex PCR were obtained
from Applied Biosystems: GAPD (Catalog#4352934E),
peptidylprolyl isomerase A (PPIA) (Catalog#4326316E),
BCL-XL (Hs00236329_m1), STAT3 (Hs00374280_m1),
STAT1 (Hs01013996_m1), OAS1 (Hs00973637_m1),
mouse Ifit1(Mm00515153_m1). Relative quantification
of gene expression was based on the reference value from
the untreated control. [34]

Flow cytometry
Cells were plated at 200,000/well in 12-well
plates the day prior to treatment. Polyplexes were
formed as above using AlexaFluor 647-labeled AllStars
www.impactjournals.com/oncotarget
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5’-RLM-RACE and sequencing

to treatment. Cells were treated with polyplexes for 2
hours then harvested 48 hours later and assayed using the
CellTiter-Glo Luminescent Cell Viability Assay (Promega)
per manufacturer’s instructions. Microplates were read
on a Centro LB 960 microplate luminometer (Berthold
Technologies).

5’ RLM-RACE was performed using the GeneRacer
Kit (Invitrogen) with some modification as previously
described. [35] Briefly, 100 ng total RNA was directly
ligated to 250 ng GeneRacer RNAOligo with T4
ligase. After phenol/chloroform extraction and ethanol
precipitation, cDNA was synthesized using random
primers. From this reaction, 1 μl was used for first round
5’RACE reaction using the GeneRacer 5’primer and
gene-specific primers (GAPD-specific reverse primer,
5’-CCTGCAAATGAGCCCCAGCCTTCTC-3’or BCL-XLspecific reverse primer, 5’-TCTACGCTTTCCACGCA
CAGTGCCC-3’) with the following cycling conditions:
1 cycle of 94 °C for 2 minutes, then 5 cycles of 94 °C for
30 seconds and 72 °C for 1 minute, then 5 cycles of 94
°C for 30 seconds and 70 °C for 1 minute, then 20 cycles
of 94 °C for 30 seconds, and 68 °C for 1 minute. Secondround 5’ RACE reaction was then performed using 1
μl of the first-round reaction and internal GeneRacer
5’ nested and gene-specific primers (GAPD-specific
nested, 5’-CGCCAGCATCGCCCCACTTGATTTT-3’or
BCL-XL-specific nested, 5’-GCTGTCCCTGGGGTGA
TGTGGAGCT-3’) using the above cycling conditions
except for an extension time of 15 seconds and 25 cycles.
PCR were performed using an Eppendorf Mastercycler
thermocycler. PCR products were run on a 3% agarose gel
containing ethidium bromide then excised and extracted
using a QIAquick Gel Extraction kit (Qiagen). Sequencing
was performed using the ABI BigDye Terminator v3.1 Cycle
Sequencing kit and subsequently analyzed on an ABI-3730xl
DNA Analyzer (Applied Biosystems) per manufacturer′s
protocol.

GAPD protein assay
GAPD enzyme activity was quantitated using the
KDAlert GAPDH assay kit (Ambion) per manufacturer’s
recommendations. Cells were treated in quadruplicate then
lysed 72 hours later. Lysate was transferred to a 96-well
plate and KDAlert master mix added. The fluorescence
intensity was measured over 4 minutes using an excitation
wavelength of 560 nm and emission wavelength of 590 nm.

Xenograft experiments
5-6 week old female athmyic nu/nu mice weighing
approximately 20 grams were obtained from Harlan
Laboratories. Animals were housed in specific pathogenfree housing. All experiments were performed with the
approval of the Fred Hutchinson Cancer Research Center
Institutional Animal Care and Use Committee. 10 million
SKOV3 luciferase-expressing cells suspended in sterile
PBS (Gibco) were injected intraperitoneally. For imaging
studies, mice were injected intraperitoneally with firefly
D-luciferin (Biosynth International, Inc; Itasca, IL) at
150 micrograms per gram of body weight and tumor
establishment was verified by in vivo bioluminescence
imaging using the Xenogen Spectrum system (Perkin
Elmer; Waltham, MA). Mice were separated into treatment
groups with similar average bioluminescence intensity and
then injected intraperitoneally with Cy5.5-labeled siRNA
alone, a trastuzumab-targeted polyplex containing Cy5.5labeled siRNA, or sterile PBS alone. After 24 hours, mice
were euthanized via carbon dioxide inhalation. Organs were
removed and imaged in an ex vivo fashion. Kidney, liver,
and tumor nodules were flash frozen for further analysis. For
functional siRNA delivery experiments, mice were injected
intraperitoneally with 2 or 4 mg/kg siRNA once daily for two
days then euthanized via carbon dioxide inhalation 72 hours
after the second dose. Blood for laboratory toxicity analysis
was harvested via cardiac puncture. Tumor and spleen were
placed in RNAlater (Qiagen) for RNA extraction for qRTPCR and 5’RACE analysis (tumor only).

Immunoblotting
Protein gel electrophoresis was performed by loading
5 μg of cell lysate per lane on a 4-12% Bis-Tris NuPAGE
gel (Invitrogen) followed by transfer to a PVDF membrane
(Invitrogen). The membrane was blocked with 5% Milk/TBS
(0.1%Tween20), prior to overnight incubation with primary
antibody incubation at 4°C. Secondary antibody probing
(Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP; Dako;
Carpinteria, CA) was done for 1 hour at room temperature.
Results were visualized using Amersham ECL Western
Blotting Detection Reagents (GE Healthcare; Pittsburg, PA)
and Amersham Hyperfilm ECL (GE Healthcare). Reprobing
to verify loading control was done after rinsing the membrane
and reblocking before subsequent antibody probing. BCL-XL
(clone 54H6), GAPD (clone 14C10), and beta-actin (clone
13E5) antibodies for immunoblotting were obtained from
Cell Signaling Technologies (Danvers, MA).

RNA extraction and quantitation from tissue
RNA was extracted from mouse tissues as previously
described. [36] Briefly, samples were homogenized in
guanidine thiocyanate lysis buffer with the FastPrep-24
instrument (MP Biomedicals; Solon, OH) and Lysing
Matrix D tubes (MP Biomedicals). Samples were
immediately centrifuged at 4°C, extracted with phenolchloroform and RNA precipitated with isopropanol and

In vitro toxicity analysis
Cells were plated in quadruplicate at a cell density
of 5,000 cells/well in white 96-well plates on the day prior
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sodium acetate (Ambion) overnight at -20°C. Further RNA
purification was performed using the RNeasy kit (Qiagen;
Valencia, CA) per manufacturer’s instructions after adding
350 μl RNEasy RLT buffer and 100 μl 100% ethanol to
the resuspended RNA pellet. Residual DNA contamination
was removed with the Turbo DNA-Free kit (Ambion). The
supernatants were collected and quantitated via UV-Vis for
concentration analysis.
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